| 000 | 01564 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515175555.0 | ||
| 264 | 0 | _c20091103 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a2542-5641 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Wei | |
| 245 | 0 | 0 |
_aAntiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. _h[electronic resource] |
| 260 |
_bChinese medical journal _cJun 2009 |
||
| 300 |
_a1250-4 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacology |
| 650 | 0 | 4 | _aAntineoplastic Combined Chemotherapy Protocols |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlioma _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aMagnetic Resonance Imaging |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aQiu, Xiao-guang | |
| 700 | 1 | _aChen, Bao-shi | |
| 700 | 1 | _aLi, Shou-wei | |
| 700 | 1 | _aCui, Yun | |
| 700 | 1 | _aRen, Huan | |
| 700 | 1 | _aJiang, Tao | |
| 773 | 0 |
_tChinese medical journal _gvol. 122 _gno. 11 _gp. 1250-4 |
|
| 999 |
_c18983872 _d18983872 |
||